Equity Briefing : Ampio Pharmaceuticals, Amylin Pharmaceuticals and Cytori Therapeutics moving higher

Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) is showing solid up movement with a gain of 11.22% to $5.65. The company announced an agreement with India-based Syngene to create a combination product to treat both premature ejaculation and erectile dysfunction in a Phase III trial. The resulted product would be known as Zertane-ED, will be used in trials in South Korea with the biopharmaceutical company's partner Daewoong Co., which will finance and conduct the trials...

Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) is showing solid up movement with a gain of 11.22% to $5.65. The company announced an agreement with India-based Syngene to create a combination product to treat both premature ejaculation and erectile dysfunction in a Phase III trial. The resulted product would be known as Zertane-ED, will be used in trials in South Korea with the biopharmaceutical company's partner Daewoong Co., which will finance and conduct the trials.

Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) added 8.83% to $30.69 and made a new 52-week high of $30.75. This morning Bristol Myers Squibb Co.(NYSE:BMY) agreed to buy the company for $5.3 billion or $31 per share in cash.

Following an acquisition of Amylin, analyst at Piper Jaffray issued a positive note on various biotech stocks and stated those companies would be an acquisition target. BioMarin Pharmaceutical Inc.(NASDAQ:BMRN) climbed 1.47 (3.71%) to $41.05, Theravance Inc(NASDAQ:THRX) added 1.77 (7.94%) at $23.99, Affymax, Inc.(NASDAQ:AFFY) rose 0.19 (1.48%) to $13.07 and Rigel Pharmaceuticals, Inc.(NASDAQ:RIGL) surged 0.13 (1.40%) to $9.43.

Cytori Therapeutics Inc. (NASDAQ:CYTX) extended its uptrend and rose another 9.26% to $2.95. The stock has been showing solid buying since early July and went up all the way from $2.05 to $2.95 in about a month. In February, the stock had sharp selloff and lost  about 50% in just one month.

Copyright Thomson Reuters


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: %s via Thomson Reuters ONE


[HUG#1623629]